A Phase 3 interventional study of Insulin glargine/lixisenatide fixed ratio combination and liraglutide in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 124 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 45th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 60 in phase 3, and was the 135th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 514 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 46th largest by enrollment of the 178 interventional ones that give a count, is one of 13 that started in 2016, is one of 80 in phase 3, and was the 140th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
Secondary Objectives:
To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 [SGLT2] inhibitor) in participants with type 2 diabetes.
To evaluate safety, efficacy and other endpoints of FRC up to the end of the extension period.
The maximum duration for GLP1-RA participants was approximately 29 weeks: up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety follow-up period.
Maximum duration for FRC participants was approximately 55 weeks: up to 2-week screening period, a 26-week randomized treatment period, a 26-week extension period and a 3-day post-treatment safety follow-up period.
All primary and secondary efficacy, safety and other outcome measures were assessed at the end of the extension period.
Inclusion criteria :
in combination with metformin (daily dose greater than equal to [>=] 1500 mg/day or maximum tolerated dose [MTD]), with or without pioglitazone, with or without SGLT2 inhibitor, all at stable dose for at least 3 months prior to screening.
or
Participants who were treated with stable dose of one of the following GLP-1 receptor agonists for at least 6 months prior to screening visit (V1):
in combination with metformin (daily dose ≥1500 mg/day or MTD), with or without pioglitazone, with or without SGLT2 inhibitor, all at stable dose for at least 3 months prior to screening;
-Signed written .
Exclusion criteria:
Exclusion criteria for the extension period:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted. Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted.
Drug: Insulin glargine/lixisenatide fixed ratio combination · Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily \[BID\], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
Drug: liraglutide · Drug: exenatide · Drug: exenatide extended-release · Drug: albiglutide · Drug: dulaglutide · Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug pages: Insulin Glargine · Lixisenatide
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: HOE901/AVE0010, Soliqua
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Victoza
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Byetta
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Bydureon
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Tanzeum
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Trulicity
Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period
Change in HbA1c was calculated by subtracting baseline value from Week 26 value. Adjusted least squares (LS) mean and standard error (SE) were obtained from Mixed-effect model with repeated measures (MMRM) to account for missing data using all available post baseline data during the 26 week treatment period.
Time frame: Baseline, Week 26
Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period
Change in HbA1c was calculated by subtracting baseline value from Week 52 value.
Time frame: Baseline, Week 52
Percentage of Participants Reaching HbA1c <7% or <=6.5% at Week 26: Core Period
Participants without any available HbA1c assessment at Week 26 were considered as non-responders.
Time frame: Week 26
Percentage of Participants Reaching HbA1c <7 % or <=6.5% at Week 52: Single Arm Extension Period
Participants without any available HbA1c assessment at Week 52 were considered as non-responders.
Time frame: Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 26: Core Period
Change in FPG was calculated by subtracting baseline value from Week 26 value. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
Time frame: Baseline, Week 26
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52: Single Arm Extension Period
Change in FPG was calculated by subtracting baseline value from Week 52 value.
Time frame: Baseline, Week 52
Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 26: Core Period
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
Time frame: Baseline, Week 26
Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 52: Single Arm Extension Period
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal.
Time frame: Baseline, Week 52
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 26: Core Period
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using last observation carried forward (LOCF).
Time frame: Baseline, Week 26
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 52: Single Arm Extension Period
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
Time frame: Baseline, Week 52
Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 26: Core Period
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF.
Time frame: Baseline, Week 26
Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 52: Single Arm Extension Period
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before IMP administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
Time frame: Baseline, Week 52
Percentage of Participants Requiring Rescue Therapy During the 26 Week Treatment Period: Core Period
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold values at Week 12 or later on Week 12: HbA1c \>8%.
Time frame: From Baseline to Week 26
Percentage of Participants Requiring Rescue Therapy During the 52 Week Treatment Period: Single Arm Extension Period
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold values at Week 12 or later on Week 12: HbA1c \>8%.
Time frame: From Week 26 to Week 52
Change From Baseline in Body Weight at Week 26: Core Period
Change in body weight was calculated by subtracting baseline value from Week 26 value.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight to Week 52: Single Arm Extension Period
Change in body weight was calculated by subtracting baseline value from Week 52 value.
Time frame: Baseline, Week 52
Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Core Period
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL). Hypoglycemic episodes with plasma glucose of \<3.0 mmol/L (54 mg/dL) were also analyzed.
Time frame: From Baseline to Week 26
Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL). Hypoglycemic episodes with plasma glucose of \<3.0 mmol/L (54 mg/dL) were also analyzed.
Time frame: From Baseline to Week 52
The study was conducted at 112 sites in 9 countries. A total of 840 participants were screened between 06 July 2016 and 01 November 2017, of which 326 were screen failures. Screen failures were mainly due to glycated hemoglobin (HbA1c) level lesser than (\<)7% or more than (\>)9% at screening visit.
| Milestone | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Started | 257 | 257 |
| Treated | 255 | 256 |
| Completed | 230 | 246 |
| Not completed | 27 | 11 |
| Withdrew: Adverse event | 10 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Poor compliance to protocol | 2 | 0 |
| Withdrew: Withdrawal by subject | 9 | 9 |
| Withdrew: Randomized but not treated | 2 | 1 |
| Withdrew: Other than specified | 3 | 1 |
| Milestone | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Started | 206 | 0 |
| Completed | 197 | 0 |
| Not completed | 9 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Poor compliance to protocol | 3 | 0 |
| Withdrew: Other than specified | 5 | 0 |
Change in HbA1c was calculated by subtracting baseline value from Week 26 value. Adjusted least squares (LS) mean and standard error (SE) were obtained from Mixed-effect model with repeated measures (MMRM) to account for missing data using all available post baseline data during the 26 week treatment period.
| percentage of HbA1c | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period | -1.02 ± 0.048 | -0.38 ± 0.048 |
Change in HbA1c was calculated by subtracting baseline value from Week 52 value.
| percentage of HbA1c | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period | -1.01 ± 0.063 |
Participants without any available HbA1c assessment at Week 26 were considered as non-responders.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| HbA1c <7% | 61.9 | 25.7 |
| HbA1c <=6.5% | 40.5 | 9.9 |
Participants without any available HbA1c assessment at Week 52 were considered as non-responders.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| HbA1c <7% | 64.1 |
| HbA1c <=6.5% | 42.7 |
Change in FPG was calculated by subtracting baseline value from Week 26 value. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
| millimoles per litre (mmol/L) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 26: Core Period | -2.28 ± 0.120 | -0.60 ± 0.119 |
Change in FPG was calculated by subtracting baseline value from Week 52 value.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52: Single Arm Extension Period | -2.27 ± 0.173 |
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 26: Core Period | -1.69 ± 0.114 | -0.67 ± 0.112 |
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 52: Single Arm Extension Period | -1.68 ± 0.176 |
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using last observation carried forward (LOCF).
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 26: Core Period | -3.96 ± 0.211 | -1.11 ± 0.205 |
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 52: Single Arm Extension Period | -4.30 ± 0.284 |
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 26: Core Period | -1.51 ± 0.177 | -0.52 ± 0.173 |
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before IMP administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 52: Single Arm Extension Period | -1.85 ± 0.209 |
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold values at Week 12 or later on Week 12: HbA1c \>8%.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Percentage of Participants Requiring Rescue Therapy During the 26 Week Treatment Period: Core Period | 4.8 | 15.0 |
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold values at Week 12 or later on Week 12: HbA1c \>8%.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Percentage of Participants Requiring Rescue Therapy During the 52 Week Treatment Period: Single Arm Extension Period | 1.5 |
Change in body weight was calculated by subtracting baseline value from Week 26 value.
| kilogram (kg) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Change From Baseline in Body Weight at Week 26: Core Period | 1.89 ± 0.222 | -1.14 ± 0.220 |
Change in body weight was calculated by subtracting baseline value from Week 52 value.
| kg | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Change From Baseline in Body Weight to Week 52: Single Arm Extension Period | 2.78 ± 0.294 |
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL). Hypoglycemic episodes with plasma glucose of \<3.0 mmol/L (54 mg/dL) were also analyzed.
| events per participant-year | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist |
|---|---|---|
| Documented symptomatic hypoglycemia(<=3.9 mmol/L) | 1.54 | 0.08 |
| Documented symptomatic hypoglycemia (<3.0 mmol/L) | 0.25 | 0.01 |
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL). Hypoglycemic episodes with plasma glucose of \<3.0 mmol/L (54 mg/dL) were also analyzed.
| events per participant-year | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) |
|---|---|
| Documented symptomatic hypoglycemia(<=3.9 mmol/L) | 1.59 |
| Documented symptomatic hypoglycemia (<3.0 mmol/L) | 0.24 |
Collected over All Adverse Events (AEs) were collected from signature of informed consent until the end of the study (up to 52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed Ratio Combination | 0/255 (0%) | 10/255 (3.9%) | 69/255 (27.1%) |
| GLP-1 Receptor Agonist | 0/256 (0%) | 9/256 (3.5%) | 48/256 (18.8%) |
| Fixed Ratio Combination Whole Study Period | 1/206 (0.5%) | 21/206 (10.2%) | 75/206 (36.4%) |
| Event | Fixed Ratio Combination | GLP-1 Receptor Agonist | Fixed Ratio Combination Whole Study Period |
|---|---|---|---|
| Cardiac Failure CongestiveCardiac disorders | 0/255 | 0/256 | 2/206 |
| Coronary Artery DiseaseCardiac disorders | 0/255 | 0/256 | 2/206 |
| FallInjury, poisoning and procedural complications | 2/255 | 0/256 | 2/206 |
| Subarachnoid HaemorrhageNervous system disorders | 0/255 | 0/256 | 2/206 |
| Arteriosclerosis Coronary ArteryCardiac disorders | 0/255 | 0/256 | 1/206 |
| Atrial FibrillationCardiac disorders | 1/255 | 0/256 | 1/206 |
| Cardiac FailureCardiac disorders | 0/255 | 0/256 | 1/206 |
| Ischaemic CardiomyopathyCardiac disorders | 1/255 | 0/256 | 1/206 |
| Duodenal UlcerGastrointestinal disorders | 0/255 | 0/256 | 1/206 |
| Rectal HaemorrhageGastrointestinal disorders | 1/255 | 0/256 | 1/206 |
| Event | Fixed Ratio Combination | GLP-1 Receptor Agonist | Fixed Ratio Combination Whole Study Period |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 25/255 | 23/256 | 32/206 |
| NauseaGastrointestinal disorders | 22/255 | 6/256 | 19/206 |
| DiarrhoeaGastrointestinal disorders | 14/255 | 6/256 | 15/206 |
| InfluenzaInfections and infestations | 11/255 | 6/256 | 15/206 |
| Upper Respiratory Tract InfectionInfections and infestations | 9/255 | 12/256 | 13/206 |
Analysis was performed on randomized population.
| Age, Continuous(years) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Mean | 59.2 ± 9.6 | 60.0 ± 10.3 | 59.6 ± 10.0 |
| Sex: Female, Male(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Female | 131 | 113 | 244 |
| Male | 126 | 144 | 270 |
| Race/Ethnicity, Customized(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian/Oriental | 3 | 4 | 7 |
| Black | 12 | 7 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 241 | 244 | 485 |
| Unknown or Not Reported' | 0 | 2 | 2 |
| Body Mass Index (BMI)(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| <30 | 71 | 69 | 140 |
| >=30 | 186 | 188 | 374 |
| Duration of diabetes(years) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Mean | 11.23 ± 7.42 | 10.95 ± 6.08 | 11.09 ± 6.78 |
| Hemoglobin A1C (HbA1C)(percentage of HbA1c) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Mean | 7.78 ± 0.62 | 7.80 ± 0.56 | 7.79 ± 0.59 |
| Daily dose of metformin at baseline(milligrams (mg)) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Mean | 1966.93 ± 434.56 | 2030.74 ± 497.15 | 1998.83 ± 467.54 |
| Daily dose of pioglitazone at baseline(mg) | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | GLP-1 Receptor Agonist | Total |
|---|---|---|---|
| Mean | 31.25 ± 10.03 | 32.73 ± 8.83 | 32.21 ± 9.14 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 124 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2016 to primary completion in May 2018, 22 months.
Results were first posted in Jun 2019, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Lixisenatide